Navigation Links
Cepheid Announces Nomination of Geisinger Health System CEO and Renowned Oncology Researcher to Board of Directors
Date:3/15/2011

SUNNYVALE, Calif., March 15, 2011 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced that Glenn Steele, Jr., MD, PhD, has been nominated for election to Cepheid's Board of Directors at the company's Annual Meeting of Shareholders to be held on April 26, 2011.

Dr. Steele has been President and Chief Executive Officer of Geisinger Health System, a physician-led health care system serving multiple regions of Pennsylvania, since 2001.  Before that, Dr. Steele served as the Richard T. Crane Professor in the Department of Surgery, Vice President for Medical Affairs, and Dean of the Biological Sciences Division and the Pritzker School of Medicine at the University of Chicago.  In addition, Dr. Steele was previously the William V. McDermott Professor of Surgery at Harvard Medical School, President and Chief Executive Officer of Deaconess Professional Practice Group and Chairman of the Department of Surgery at New England Deaconess Hospital.

"With extensive experience in the healthcare industry, as a noted surgeon, researcher and now CEO of a large hospital group, Glenn will bring an invaluable perspective to the Cepheid Board," said John Bishop, Cepheid's Chief Executive Officer.  "Additionally, as a renowned researcher in the fields of liver and colorectal cancers, Dr. Steele will also further strengthen our Board just as Cepheid is moving more aggressively to extend the reach of our Xpert® test portfolio into oncology."

Dr. Steele serves on the boards of Bucknell University, Temple University School of Medicine, Premier Inc. as Vice Chair, Weis Markets Inc., Wellcare Health Plans Inc., and the American Hospital Association Committee of Research.  

About CepheidBased in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy to use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to access the full power of molecular diagnostics. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit www.cepheid.com.

Securities Law DisclosuresThe solicitation of proxies for the election of directors is made pursuant to a proxy statement filed with United States Securities and Exchange Commission. Cepheid shareholders and other investors are advised to read carefully the proxy statement relating to Cepheid's 2011 annual meeting of shareholders and any other relevant documents filed by Cepheid with the United States Securities and Exchange Commission before making any voting decision, because they contain important information.

Copies of the proxy statement and any other relevant documents are available to Cepheid shareholders at no expense to them.  In addition, those materials are available without charge from Cepheid Investor Relations at (408) 400-8329 or by email at investor.relations@cepheid.com, or the United States Securities and Exchange Commission through the Commission's website at www.sec.gov.  CONTACTS:For Media Inquiries:For Investor Inquiries:Jared Tipton

Cepheid Corporate Communications

Tel: (408) 400-8377

communications@cepheid.com

Jacquie Ross

Cepheid Investor Relations

Tel: (408) 400-8329

investor.relations@cepheid.com
'/>"/>

SOURCE Cepheid
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
2. Cepheid Launches New GeneXpert(R) Tests in Europe for Simultaneous, Rapid Detection of Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus
3. Cepheid GeneXpert(R) System and Xpert(TM) MRSA Selected for up to 11 Victoria, Australia Hospitals in Rollout of Start Clean Strategy
4. Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection
5. Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized Moderate Complexity by FDA
6. Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin
7. Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System
8. Cepheid Reports 2009 Third Quarter Results
9. Cepheid to Webcast Upcoming Financial Presentations
10. Cepheid Collaborates With Pharmaceutical Leader on Chronic Myelogenous Leukemia
11. Cepheid to Webcast Upcoming Financial Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
Breaking Medicine News(10 mins):